Stable angina is chest discomfort precipitated by physical exertion or emotional distress due to myocardial oxygen supply-demand mismatch, most commonly from fixed atherosclerotic coronary obstruction. Nearly 10 million US adults are affected. [1] The hallmark is predictable, exertional chest discomfort that resolves with rest or nitroglycerin within minutes. [1]
1. History
- Character: Retrosternal pressure, heaviness, tightness, squeezing, or constriction — not sharp or stabbing [2]
- Onset/Duration: Gradual build over minutes; fleeting pain (seconds) is unlikely ischemic [2]
- Triggers: Physical exertion, emotional stress, cold exposure, heavy meals [2]
- Relieving factors: Rest (typically within 1–5 minutes), sublingual nitroglycerin (note: relief with NTG is not diagnostic of ischemia) [2]
- Radiation: Jaw, neck, left arm, both arms, or interscapular area; pain localizable to a fingertip or below the umbilicus is unlikely ischemic [2]
- Severity grading: Use the Canadian Cardiovascular Society (CCS) classification (Class I–IV) to quantify functional limitation [1]
- Quality of life impact: Assess angina frequency, functional limitation, and activities the patient cannot perform; the Seattle Angina Questionnaire-7 is a practical validated tool [1]
- Important negatives: Pleuritic component, positional variation, reproducibility with palpation — all reduce likelihood of ischemic etiology [3]
2. Alarm Features
- Rest angina or angina with minimal exertion → suggests ACS (unstable angina/NSTEMI) [2][4]
- Crescendo pattern — increasing frequency, severity, or duration of previously stable angina
- New-onset angina with severe functional limitation (CCS III–IV)
- Associated hemodynamic instability: hypotension, syncope, diaphoresis, new heart failure symptoms
- Sudden-onset ripping/tearing pain radiating to back → aortic dissection [2]
- New ST-segment changes or troponin elevation → reclassifies as ACS [4-5]
- Angina with new murmur → consider acute MR (papillary muscle ischemia) or aortic stenosis
3. Medications
First-line antianginal therapy (2023 AHA/ACC, Class 1 recommendation): beta-blocker, CCB, or long-acting nitrate: [6]
- Beta-blockers: Metoprolol tartrate 25–100 mg BID, atenolol 50–200 mg daily, bisoprolol 5–10 mg daily. Preferred with prior MI, LV dysfunction, elevated HR/BP [7]
- CCBs: Amlodipine 5–10 mg daily (dihydropyridine); diltiazem ER 120–480 mg daily or verapamil ER 120–480 mg daily (non-dihydropyridine). Non-DHPs preferred with elevated HR; avoid in significant LV dysfunction [6-7]
- Long-acting nitrates: Isosorbide mononitrate 30–120 mg daily. Require a nitrate-free interval (10–12 hours) to prevent tolerance [7]
Second-line / Add-on:
- Ranolazine 375–750 mg BID — recommended for persistent symptoms despite first-line agents; neutral hemodynamic profile; preferred in diabetes; contraindicated in severe hepatic/renal impairment (QT prolongation risk) [6-7]
- Sublingual NTG 0.4 mg PRN for breakthrough angina; can be used prophylactically before known triggers [6]
Key contraindications and cautions:
- Nitrates + PDE-5 inhibitors (sildenafil, tadalafil) → severe hypotension; absolutely contraindicated [7]
- Non-DHP CCBs + beta-blockers → risk of bradycardia, AV block, hypotension; use with caution [6]
- Beta-blockers in vasospastic angina → contraindicated (can precipitate α-mediated vasospasm) [7]
- Nitrates in obstructive HCM, severe aortic/mitral stenosis → contraindicated [7]
- Ivabradine in patients with normal LV function → potentially harmful per AHA/ACC (Class 3: Harm) [6]
- Do not abruptly discontinue beta-blockers → rebound tachycardia and vasoconstriction [7]
Secondary prevention (GDMT):
- High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) [1]
- Aspirin 75–100 mg daily (or clopidogrel if aspirin-intolerant) [1]
- BP target <130/80 mmHg [1]
- SGLT2 inhibitors or GLP-1 RAs preferred for CV risk reduction in type 2 diabetes with CAD [1]
4. Diet
- Mediterranean diet or DASH-style dietary pattern — associated with reduced cardiovascular events [7]
- Limit saturated fat, trans fat, and sodium intake
- Moderate alcohol consumption; avoid excess
- Adequate hydration; avoid large heavy meals (can trigger angina via splanchnic blood flow redistribution)
- Weight management: target BMI <30 as obesity is a modifiable risk factor [1]
5. Review of Systems
- Cardiovascular: Dyspnea on exertion, orthopnea, PND, palpitations, lower extremity edema, claudication
- Pulmonary: Pleuritic pain, cough (rule out PE, pneumonia)
- GI: Heartburn, dysphagia (GERD mimics angina in 10–15% of chest pain presentations) [3]
- Musculoskeletal: Reproducible chest wall tenderness (costochondritis accounts for 20–50% of chest pain) [3]
- Neuropsychiatric: Anxiety, panic symptoms (psychiatric causes can mimic ACS) [8]
- Endocrine: Symptoms of thyroid disease (hyperthyroidism lowers anginal threshold)
6. Collateral History and Family History
- Family history of premature CAD: First-degree relative with CVD before age 55 (male) or 65 (female)
- Family history of sudden cardiac death — raises concern for inherited cardiomyopathy
- Collateral from family regarding symptom progression, functional decline, medication adherence
- Social context: Tobacco use (current or recent), cocaine/stimulant use, occupational physical demands, psychosocial stressors
7. Risk Factors
- Major: Hypertension, hyperlipidemia, diabetes mellitus, tobacco use, family history of premature CAD, obesity, chronic kidney disease [8-9]
- Lifestyle: Sedentary behavior, poor diet, excessive alcohol
- Comorbidities increasing risk: Peripheral arterial disease, prior MI or revascularization, prior stroke/TIA, chronic kidney disease, metabolic syndrome [8]
- Emerging: Elevated hs-CRP, coronary artery calcium score, elevated Lp(a)
- Demographics: Male sex, older age (≥65), postmenopausal women
8. Differential Diagnosis
Cannot-miss diagnoses:
- Acute coronary syndrome (unstable angina, NSTEMI, STEMI) — rest pain, crescendo pattern, ECG changes, troponin elevation [4-5]
- Aortic dissection — sudden tearing pain radiating to back, BP differential between arms [2]
- Pulmonary embolism — pleuritic pain, dyspnea, tachycardia, risk factors for VTE
- Tension pneumothorax — acute dyspnea, unilateral absent breath sounds
Common mimics:
- GERD/esophageal spasm (10–15% of chest pain) — burning, postprandial, positional [3]
- Musculoskeletal/costochondritis (20–50%) — reproducible with palpation [3]
- Aortic stenosis — exertional angina with crescendo-decrescendo murmur [1]
- Hypertrophic cardiomyopathy — exertional symptoms, dynamic LVOT obstruction [1]
- Pulmonary hypertension — exertional dyspnea, loud P2, RV heave [1]
- Vasospastic (Prinzmetal) angina — rest angina, often nocturnal, transient ST elevation
- Cardiac syndrome X / microvascular angina (INOCA) — angina with nonobstructive coronaries [7]
- Panic disorder/anxiety — episodic, associated with hyperventilation, palpitations [8]
9. Past Medical History
- Prior MI, PCI, or CABG — changes pretest probability and management pathway
- Known CAD with prior angiographic data
- Heart failure (LVEF assessment critical for treatment decisions)
- Valvular heart disease (especially aortic stenosis)
- Diabetes mellitus, CKD, peripheral vascular disease
- Prior stress test or CCTA results
- Medication history including prior antianginal trials and tolerability
10. Physical Exam
- Vital signs: BP in both arms (dissection screen), HR, SpO2; hypertension and tachycardia increase myocardial oxygen demand
- Cardiac auscultation:
- S4 gallop (diastolic dysfunction, common in CAD)
- New S3 (LV dysfunction)
- Crescendo-decrescendo systolic murmur → aortic stenosis vs. HCM (distinguish with Valsalva: HCM murmur increases, AS decreases) [1]
- Holosystolic murmur → mitral regurgitation (papillary muscle dysfunction)
- Loud P2 → pulmonary hypertension [1]
- Chest wall: Reproducible tenderness suggests musculoskeletal etiology (LR 0.3 for ACS) [3]
- Peripheral vascular: Diminished pulses, bruits (carotid, femoral) → systemic atherosclerosis
- Signs of heart failure: JVD, peripheral edema, pulmonary crackles
- Xanthomas, xanthelasma → familial hyperlipidemia
11. Lab Studies
- Baseline labs: CBC (anemia lowers anginal threshold), BMP (renal function, electrolytes), fasting lipid panel, fasting glucose/HbA1c, TSH [1]
- Troponin: Normal in stable angina; elevation reclassifies to ACS. However, chronic low-level hs-cTn elevation in CCD identifies higher-risk patients [1]
- BNP/NT-proBNP: Elevated levels suggest LV dysfunction or heart failure; provides additional prognostic information [1]
- Monitoring: Annual lipid panel, HbA1c, renal function for patients on GDMT
- Rule-out labs in ED: Serial high-sensitivity troponin (0h/1h or 0h/3h protocol) to exclude ACS [5]
12. Imaging
First-line (no known CAD):
- Coronary CT angiography (CCTA) — Class 1 recommendation for intermediate-high risk patients with stable chest pain and no known CAD; high sensitivity (95–99%), high negative predictive value; detects nonobstructive plaque missed by stress testing [1-2]
- Stress imaging (stress echo, SPECT MPI, PET MPI, stress CMR) — also Class 1; effective for diagnosis of ischemia and risk stratification [2]
- Exercise ECG — reasonable if interpretable ECG and ability to exercise ≥5 METs (Class 2a) [2]
Known CAD with worsening symptoms:
- Stress PET/SPECT MPI, CMR, or stress echo recommended [2][6]
- Invasive coronary angiography (ICA) recommended for persistent symptoms despite GDMT to guide revascularization decisions [6]
Gold standard: Invasive coronary angiography with FFR/iFR for hemodynamic significance
When imaging is unnecessary: Routine periodic stress testing or CCTA is not recommended in stable patients without a change in clinical or functional status (Class 3: No Benefit) [6]
The following figure summarizes the diagnostic approach to stable chest pain:
13. Special Tests
- Pretest probability calculators: Diamond-Forrester model, CAD Consortium 2 score — estimate likelihood of obstructive CAD to guide testing decisions [1]
- Seattle Angina Questionnaire (SAQ-7): Validated patient-reported outcome tool for angina burden and quality of life [1]
- Canadian Cardiovascular Society (CCS) Classification: Grades I–IV for functional severity
- Fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR): Invasive assessment of hemodynamic significance of intermediate stenoses
- FFR-CT: Noninvasive CT-derived FFR for 40–90% stenoses on CCTA (Class 2a) [2]
- Coronary artery calcium (CAC) score: Useful for risk stratification in asymptomatic patients; less role in symptomatic evaluation
- Echocardiography: Assess LV function, wall motion abnormalities, valvular disease — particularly if abnormal ECG, elevated biomarkers, or murmur [1-2]
14. ECG
- Resting ECG should be performed in all patients to screen for prior infarction (Q waves), LV hypertrophy, ST-T wave abnormalities, arrhythmias, and bundle branch blocks [1]
- Resting ECG is often normal in stable angina between episodes
- During ischemia: Horizontal or downsloping ST depression ≥1 mm, T-wave inversions
- Exercise ECG findings suggesting high risk: ≥2 mm ST depression, ST depression at low workload (<5 METs), ST depression in ≥5 leads, exercise-induced ST elevation (non-Q-wave lead), failure to increase SBP or drop in SBP with exercise, sustained VT [1]
- Dangerous patterns to recognize: New ST elevation (STEMI), dynamic ST changes at rest (ACS), new LBBB
- Periodic resting ECG in CCD provides a baseline for comparison during future symptomatic episodes [6]
15. Assessment
Clinical summary: Stable angina is a chronic condition reflecting fixed obstructive CAD (or microvascular dysfunction) with predictable, exertion-related symptoms. It exists on a continuum with ACS, and the critical clinical task is distinguishing stable from unstable presentations. [1][11]
Severity stratification (2023 AHA/ACC): Classify annual risk of CV death or nonfatal MI as low (<1%), intermediate (1–3%), or high (>3%) using all available clinical, noninvasive, and invasive data. [6]
Typical vs. atypical presentations:
- Typical: Substernal pressure with exertion, relieved by rest/NTG within minutes
- Atypical presentations more common in women, elderly, and patients with diabetes — may present with dyspnea, fatigue, or epigastric discomfort as anginal equivalents [5][8]
Complications: Progression to ACS, heart failure from chronic ischemia, ischemic cardiomyopathy, arrhythmias, sudden cardiac death [11]
16. Treatment Plan
Initial stabilization (ED):
- If concern for ACS: ECG within 10 minutes, serial hs-troponin, aspirin 325 mg, IV access [5]
- If stable angina confirmed: sublingual NTG 0.4 mg for acute symptom relief [6]
Optimal medical therapy (OMT):
- Antianginal: Beta-blocker or CCB first-line → add second agent from different class if persistent symptoms → add ranolazine if refractory. SL NTG PRN for breakthrough [6]
- Secondary prevention: High-intensity statin, aspirin 75–100 mg, BP <130/80, SGLT2i or GLP-1 RA in diabetics [1]
- Lifestyle: Smoking cessation, structured exercise (cardiac rehab), Mediterranean diet, weight management [1][7]
Revascularization:
- PCI does not reduce MI or death in stable angina (COURAGE, ISCHEMIA trials) but significantly improves quality of life and angina burden — reserve for patients with symptoms refractory to or intolerant of OMT [1][9]
- CABG offers survival benefit in left main disease, 3-vessel disease with diabetes, and severe LV dysfunction (LVEF ≤35%) [7][9][12]
- Shared decision-making is essential — patients must understand PCI improves symptoms but not longevity [1]
17. Disposition
Discharge from ED (most stable angina patients):
- Hemodynamically stable, no ECG changes, negative serial troponins, symptoms consistent with known stable pattern
- Adequate outpatient follow-up arranged
Admission criteria:
- New or accelerating angina pattern (reclassified as unstable angina/ACS)
- Positive troponin or dynamic ECG changes
- Hemodynamic instability, new heart failure, arrhythmia
- High-risk stress test findings requiring urgent angiography
Specialist consultation triggers:
- Refractory angina despite optimized dual or triple antianginal therapy
- High-risk noninvasive test results (large area of ischemia, LV dysfunction)
- Suspected left main or 3-vessel disease
- Need for revascularization decision-making (cardiology/cardiac surgery)
18. Follow-Up / Return Precautions
Follow-up timing:
- New diagnosis: Cardiology referral within 2–4 weeks for risk stratification and diagnostic testing [6]
- After medication initiation: Reassess in 2–4 weeks for efficacy and tolerability; titrate as needed [1]
- Stable patients on GDMT: Periodic outpatient visits; no routine periodic stress testing, CCTA, LV function reassessment, or invasive angiography if clinically stable (Class 3: No Benefit/Harm) [6]
Return precautions — instruct patients to seek immediate care for:
- Chest pain at rest or with minimal exertion
- Angina lasting >15–20 minutes or not relieved by 3 doses of SL NTG (5 minutes apart)
- Increasing frequency or severity of angina episodes
- New dyspnea, syncope, presyncope, or diaphoresis with chest pain
- Palpitations or lightheadedness
Patient counseling:
- Carry SL NTG at all times; replace every 6 months (tablets) or check expiration (spray)
- Avoid PDE-5 inhibitors within 24 hours (sildenafil) or 48 hours (tadalafil) of nitrate use
- Expected recovery: Stable angina is a chronic condition managed long-term; most patients achieve good symptom control with OMT [1]
References
1. Diagnosis and Management of Stable Angina: A Review. — Joshi PH, de Lemos JA. The Journal of the American Medical Association. 2021.
2. Diagnosis and Management of Stable Angina: A Review. — Joshi PH, de Lemos JA. The Journal of the American Medical Association. 2021.
3. Diagnosis and Management of Stable Angina: A Review. — Joshi PH, de Lemos JA. The Journal of the American Medical Association. 2021.
4. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021.
5. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021.
6. Acute Coronary Syndrome: Diagnosis and Initial Management. — Nohria R, Viera AJ. American Family Physician. 2024.
7. Acute Coronary Syndrome: Diagnosis and Initial Management. — Nohria R, Viera AJ. American Family Physician. 2024.
8. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Rao SV, O'Donoghue ML, Ruel M, et al. Journal of the American College of Cardiology. 2025.
9. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Rao SV, O'Donoghue ML, Ruel M, et al. Journal of the American College of Cardiology. 2025.
10. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. — Bhatt DL, Lopes RD, Harrington RA. The Journal of the American Medical Association. 2022.
11. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. — Bhatt DL, Lopes RD, Harrington RA. The Journal of the American Medical Association. 2022.
12. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. — Virani SS, Newby LK, Arnold SV, et al. Journal of the American College of Cardiology. 2023.
13. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. — Virani SS, Newby LK, Arnold SV, et al. Journal of the American College of Cardiology. 2023.
14. Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions. — Montone RA, Rinaldi R, Niccoli G, et al. Journal of the American College of Cardiology. 2024.
15. Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions. — Montone RA, Rinaldi R, Niccoli G, et al. Journal of the American College of Cardiology. 2024.
16. 2014 AHA/ACC Guideline for the Management of Patients With Non-St-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. — Amsterdam EA, Wenger NK, Brindis RG, et al. Journal of the American College of Cardiology. 2014.
17. 2014 AHA/ACC Guideline for the Management of Patients With Non-St-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. — Amsterdam EA, Wenger NK, Brindis RG, et al. Journal of the American College of Cardiology. 2014.
18. The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. — Khorsandi M, Blumenthal RS, Blaha MJ, Kohli P. Clinical Cardiology. 2024.
19. The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. — Khorsandi M, Blumenthal RS, Blaha MJ, Kohli P. Clinical Cardiology. 2024.
20. Noninvasive Cardiac Testing. — Cayley WE. American Family Physician. 2024.
21. Noninvasive Cardiac Testing. — Cayley WE. American Family Physician. 2024.
22. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. — Fihn SD, Gardin JM, Abrams J, et al. Journal of the American College of Cardiology. 2012.
23. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. — Fihn SD, Gardin JM, Abrams J, et al. Journal of the American College of Cardiology. 2012.
24. Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. — Ferraro R, Latina JM, Alfaddagh A, et al. Journal of the American College of Cardiology. 2020.
25. Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. — Ferraro R, Latina JM, Alfaddagh A, et al. Journal of the American College of Cardiology. 2020.